ISPOR recently released their award winners from their 2025 conference this May. Winners are listed below.
I’m excited to announce that my podium presentation “Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection” received an award for the Best General Podium Research Presentation. This was research conducted with co-authors Rahul Shenolikar, Rachel Salomonsen, Anuj Shah, Shanshan Wang, Stephanie Wise; Sukhvinder Johal, Sara Sullivan and Sanjana Muthukrishnan.
Best General Poster Research Presentations
CO132: Predictors of Low Disease Activity/ Remission Amongst Rheumatoid Arthritis Patients Experiencing Inadequate Response to Biologic/ Targeted Synthetic Disease-Modifying Antirheumatic Drugs. Chandrasekar Gopalakrishnan, OM1, Inc., Boston, MA, USAEE93: Estimated Total Cost of Care (TCC) of First-Line (1L) Fixed-Duration BCL2i versus Treat-To-Progression BTKi Regimens in Patients with Chronic Lymphocytic Leukemia (CLL) in the United States (US): A Population-Based Model. Sophia S. Li, Genentech, Inc., South San Francisco, CA, USAEPH5: Disability Progression and Associated Costs in Incident Early-Onset Myasthenia Gravis Patients in France A Longitudinal Cohort Study. Cecile Blein, Argenx, Zwijnaarde, BelgiumPT10: Patient-Reported Outcome Endpoint Emulation in Heart Failure External Control Arm Study (EMULATE-HF PRO-ECA Study).Presenting Author: Onyeka Illoh, Department of Practice, Sciences, & Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
Best Student Poster Research Presentations
EE403: Estimating the Family Spillover Effects of Cardiovascular Diseases: Evidence from the Medical Expenditure Panel Survey. Ruixi Yu, University of Southern California, Department of Pharmaceutical and Health Economics, School of Pharmacy, Los Angeles, CA, USAEPH152: Trends in Cardiovascular and Cancer Mortality Among Texas Residents with Cancer between 2010 and 2019. Ted Sohn, University of Texas College of Pharmacy, Graduate Student, Austin, TX, USAPT30: Evolving Trends in Racial and Ethnic Disparities in Syphilis Prevalence Among People Who are Pregnant in The United States from 2016 To 2023.Presenting Author: Yizhi Liang, University of Southern California, Department of Pharmaceutical and Health Economics, School of Pharmacy, Los Angeles, CA, USA
Best New Investigator Poster Research Presentations
PCR198: Evaluating the Influence of User-Complexity on Individual Preferences for Upper Limb Prosthetic Selection: Measurement Tool Development for a Discrete Choice Experiment. Leslie Wilson, University of California, San Francisco, San Francisco, CA, USAPT13: Clinician-Reported Outcomes—A Rare Opportunity for Orphan Labels? Kristen A. Cribbs, Alkemi, Manchester Center, VT, USAPT38: Assessing the Impact of Digital Ecosystem Engagement on Outcomes in Sickle Cell Disease (SCD) Patients. Orlando Agrippa, Sanius He.alth, London, United Kingdom
Best General Podium Research Presentations
P2: Healthcare Resource Utilization (HCRU) and Cost among Patients with Metastatic Melanoma Receiving Nivolumab + Relatlimab (NIVO+RELA) or Nivolumab + Ipilimumab (NIVO+IPI) in the Optum Database. Justin Moser, HonorHealth Research and Innovation Institute, Scottsdale, AZ, USAP17: Health Inequality Aversion in the United States and Americans’ Views on Health Inequality. Julia F. Slejko, University of Maryland School of Pharmacy, Associate Professor, Baltimore, MD, USAP38: Cost-Effectiveness of Belimumab for the Treatment of Adults with Active Lupus Nephritis in Canada. Justin Riemer, GSK, Mississauga, ON, CanadaP50: Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection.Jason Shafrin, FTI Consulting, Los Angeles, CA, USA
Best Student Podium Research Presentations
P39: Cost-Effectiveness of Transthyretin Stabilizing Agents for the Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Kanya Shah, University of Illinois Chicago, Department of Pharmacy Systems, Outcomes, and Policy, Chicago, IL, USAP40: Cost-Effectiveness Analysis of Second-Generation Antipsychotic Long-Acting Injectables in Patients with Schizophrenia in the United States. Cindy M. Chan, University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, USAP57: Frequency of ICER Miscalculation and Misinterpretation in Published Cost-Effectiveness Analysis Comparing More Than Two Alternatives.Presenting Author: Sarah McCord, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
Best New Investigator Podium Research Presentations
P6: From Research to Policy: Incorporating Patient Preferences for Colorectal Cancer Treatments into Health Technology Assessment. Carina Oedingen, University of Calgary, Cumming School of Medicine, Calgary, CanadaP13: Leveraging Real-World Data and NLP to Identify at Risk Metabolic Dysfunction Associated Steatohepatitis in the General Population. Or Shaked, Briya, Tel Aviv, IsraelP16: The Impact of Hallucinations in Synthetic Health Data on Prognostic Machine Learning Models. Lisa Pilgram, Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, CanadaP53: Alignment Between CDA Recommendations and pCPA Negotiation Outcomes: Exploring Factors Influencing Reimbursement Success.Mackenzie Mills, HTA-Hive, London, United Kingdom
